JP2022519882A5 - - Google Patents

Info

Publication number
JP2022519882A5
JP2022519882A5 JP2021546892A JP2021546892A JP2022519882A5 JP 2022519882 A5 JP2022519882 A5 JP 2022519882A5 JP 2021546892 A JP2021546892 A JP 2021546892A JP 2021546892 A JP2021546892 A JP 2021546892A JP 2022519882 A5 JP2022519882 A5 JP 2022519882A5
Authority
JP
Japan
Prior art keywords
adenosine deaminase
modification
gsd1a
base editor
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021546892A
Other languages
English (en)
Japanese (ja)
Other versions
JP7631209B2 (ja
JP2022519882A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/018124 external-priority patent/WO2020168088A1/en
Publication of JP2022519882A publication Critical patent/JP2022519882A/ja
Publication of JP2022519882A5 publication Critical patent/JP2022519882A5/ja
Priority to JP2025017262A priority Critical patent/JP7906912B2/ja
Application granted granted Critical
Publication of JP7631209B2 publication Critical patent/JP7631209B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021546892A 2019-02-13 2020-02-13 糖原病1a型を治療するための組成物および方法 Active JP7631209B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025017262A JP7906912B2 (ja) 2019-02-13 2025-02-05 糖原病1a型を治療するための組成物および方法

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US201962805271P 2019-02-13 2019-02-13
US62/805,271 2019-02-13
US201962852224P 2019-05-23 2019-05-23
US201962852228P 2019-05-23 2019-05-23
US62/852,228 2019-05-23
US62/852,224 2019-05-23
US201962876354P 2019-07-19 2019-07-19
US62/876,354 2019-07-19
US201962912992P 2019-10-09 2019-10-09
US62/912,992 2019-10-09
US201962931722P 2019-11-06 2019-11-06
US62/931,722 2019-11-06
US201962941569P 2019-11-27 2019-11-27
US62/941,569 2019-11-27
US202062966526P 2020-01-27 2020-01-27
US62/966,526 2020-01-27
PCT/US2020/018124 WO2020168088A1 (en) 2019-02-13 2020-02-13 Compositions and methods for treating glycogen storage disease type 1a

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025017262A Division JP7906912B2 (ja) 2019-02-13 2025-02-05 糖原病1a型を治療するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2022519882A JP2022519882A (ja) 2022-03-25
JP2022519882A5 true JP2022519882A5 (cg-RX-API-DMAC7.html) 2023-02-17
JP7631209B2 JP7631209B2 (ja) 2025-02-18

Family

ID=72045644

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021546892A Active JP7631209B2 (ja) 2019-02-13 2020-02-13 糖原病1a型を治療するための組成物および方法

Country Status (8)

Country Link
US (1) US20220127594A1 (cg-RX-API-DMAC7.html)
EP (1) EP3924478A4 (cg-RX-API-DMAC7.html)
JP (1) JP7631209B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210129108A (cg-RX-API-DMAC7.html)
CN (2) CN114026237B (cg-RX-API-DMAC7.html)
AU (1) AU2020221355B2 (cg-RX-API-DMAC7.html)
CA (1) CA3128886A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020168088A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3765615T3 (pl) 2018-03-14 2023-11-13 Arbor Biotechnologies, Inc. Nowe enzymy i układy crispr ukierunkowane na dna
WO2019217942A1 (en) 2018-05-11 2019-11-14 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
WO2019222555A1 (en) 2018-05-16 2019-11-21 Arbor Biotechnologies, Inc. Novel crispr-associated systems and components
EP3850088A4 (en) 2018-09-07 2023-07-19 Beam Therapeutics, Inc. Compositions and methods for improving base editing
KR20210055733A (ko) 2018-09-07 2021-05-17 빔 테라퓨틱스, 인크. 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법
JP7646552B2 (ja) 2019-01-31 2025-03-17 ビーム セラピューティクス インク. 低減された非標的脱アミノ化を有する核酸塩基エディターおよび核酸塩基エディターの特徴づけのためのアッセイ
US12600971B2 (en) 2019-02-13 2026-04-14 Beam Therapeutics Inc. Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
WO2020168135A1 (en) 2019-02-13 2020-08-20 Beam Therapeutics Inc. Compositions and methods for treating alpha-1 antitrypsin deficiency
US12594301B2 (en) 2019-09-27 2026-04-07 Beam Therapeutics Inc. Compositions and methods for treatment of liquid cancers
AU2020397041A1 (en) * 2019-12-04 2022-06-09 Arbor Biotechnologies, Inc. Compositions comprising a nuclease and uses thereof
EP4103705A4 (en) * 2020-02-14 2024-02-28 Ohio State Innovation Foundation Nucleobase editors and methods of use thereof
AU2021347359A1 (en) 2020-09-25 2023-05-18 Beam Therapeutics Inc. Fratricide resistant modified immune cells and methods of using the same
US20230383277A1 (en) * 2020-10-14 2023-11-30 Beam Therapeutics Inc. Compositions and methods for treating glycogen storage disease type 1a
EP4504947A4 (en) * 2022-04-07 2026-03-25 Univ Duke COMPOSITIONS AND METHODS TO PROMOTE LIVER REGENERATION BY GENE EDITING IN METABOLIC LIVER DISEASE
CN117568313B (zh) * 2024-01-15 2024-04-26 上海贝斯昂科生物科技有限公司 基因编辑组合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070632A2 (en) * 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
US11866727B2 (en) * 2015-11-06 2024-01-09 Crispr Therapeutics Ag Materials and methods for treatment of glycogen storage disease type 1A
ES3030658T3 (en) * 2016-03-30 2025-07-01 Intellia Therapeutics Inc Lipid nanoparticle formulations for crispr/cas components
WO2018020323A2 (en) * 2016-07-25 2018-02-01 Crispr Therapeutics Ag Materials and methods for treatment of fatty acid disorders
WO2018027078A1 (en) * 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
KR102709603B1 (ko) * 2017-02-28 2024-09-27 보르 바이오파마 인크. 계통 특이적 단백질의 억제를 위한 조성물 및 방법
CN111328290A (zh) * 2017-06-26 2020-06-23 博德研究所 用于靶向核酸编辑的基于crispr/cas-腺嘌呤脱氨酶的组合物、系统和方法
US10392616B2 (en) * 2017-06-30 2019-08-27 Arbor Biotechnologies, Inc. CRISPR RNA targeting enzymes and systems and uses thereof
EP3658573A1 (en) * 2017-07-28 2020-06-03 President and Fellows of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
KR102853088B1 (ko) * 2018-05-11 2025-09-02 빔 테라퓨틱스, 인크. 프로그래밍가능한 염기 편집기 시스템을 이용하여 단일염기다형성을 편집하는 방법
US20230235309A1 (en) * 2020-02-05 2023-07-27 The Broad Institute, Inc. Adenine base editors and uses thereof

Similar Documents

Publication Publication Date Title
JP2022520081A5 (cg-RX-API-DMAC7.html)
JP2022546608A5 (cg-RX-API-DMAC7.html)
JP2025170240A5 (cg-RX-API-DMAC7.html)
JP2022533673A5 (cg-RX-API-DMAC7.html)
JP2024038327A5 (cg-RX-API-DMAC7.html)
CN101198694B (zh) 具有经修饰的特异性的I-CreI大范围核酸酶变体、其制备方法及应用
JP2022519761A5 (cg-RX-API-DMAC7.html)
EP3060658B1 (en) Design of rare-cutting endonucleases for efficient and specific targeting dna sequences comprising highly repetitive motives
JP2025181841A5 (cg-RX-API-DMAC7.html)
US8715992B2 (en) I-CreI meganuclease variants with modified specificity, method of preparation and uses thereof
JP2022545950A5 (cg-RX-API-DMAC7.html)
JP2025102768A5 (cg-RX-API-DMAC7.html)
WO2017215648A1 (zh) 基因敲除方法
JP2024511163A5 (cg-RX-API-DMAC7.html)
Choi et al. Base editing strategies to convert CAG to CAA diminish the disease-causing mutation in Huntington’s disease
JP2022532139A5 (cg-RX-API-DMAC7.html)
JP2023545497A5 (cg-RX-API-DMAC7.html)
JP2024511131A5 (cg-RX-API-DMAC7.html)
Gutiérrez et al. Mechanism of stimulation of DNA replication by bacteriophage phi 29 single-stranded DNA-binding protein p5
US12558437B2 (en) Compositions and methods for epigenetic regulation of HBV gene expression
JP2024534639A5 (cg-RX-API-DMAC7.html)
KR20220112698A (ko) 교정 효율이 개선된 프라임에디팅용 조성물
JP2024518413A5 (cg-RX-API-DMAC7.html)
CN117568313A (zh) 基因编辑组合物及其用途
JP2022526670A5 (cg-RX-API-DMAC7.html)